Senores Pharmaceuticals reported audited FY26 consolidated net profit of ₹121.53 crores with revenue from operations at ₹401.70 crores, showing strong annual growth.
The Board approved the resignation of Company Secretary Vinay Kumar Mishra effective June 10, 2026, and appointed Sharp & Tannan Associates as Internal Auditor for FY26-27.
Statutory auditors Pankaj R. Shah & Associates issued unmodified opinions on both standalone and consolidated financial results for the year ended March 31, 2026.
The company completed significant acquisitions including 75% of Apnar Pharma and 51% of Zoraya Pharmaceuticals, strengthening its US market presence and vertical integration.